{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Azitra Inc Common Stock"},"Symbol":{"label":"Symbol","value":"AZTR"},"Address":{"label":"Address","value":"21 BUSINESS PARK DRIVE,SUITE 6, BRANFORD, Connecticut, 06405, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":null},"Sector":{"label":"Sector","value":null},"Region":{"label":"Region","value":null},"CompanyDescription":{"label":"Company Description","value":"Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease."},"CompanyUrl":{"label":"Company Url","value":null},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Francisco D. Salva","title":"President, Chief Executive Officer & Director"},{"name":"Travis Whitfill","title":"Chief Operating Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}